Back to search

Article

First-Line Pembrolizumab Plus Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A United States-Based Cost-Effectiveness Analysis

2021-08-31

Abstract excerpt

<h4>Background: </h4> The clinical trial of Keynote-604 showed that pembrolizumab plus chemotherapy could generate clinical benefits for Extensive-Stage Small-Cell Lung Cancer (ES-SCLC). We aim to assess the efficacy and cost of pembrolizumab combined with chemotherapy in the first-line treatment setting of ES-SCLC from the United States (US) payers’ perspective. <h4>Methods: </h4>: A synthetical Markov model was...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
4657016b-7033-51e6-956c-73e7de644786
DOI
10.21203/rs.3.rs-811938/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
First-Line Pembrolizumab Plus Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A United States-Based Cost-Effectiveness AnalysisDOI 10.21203/rs.3.rs-811938/v1
First-Line Pembrolizumab Plus Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness AnalysisSemantic proximity
Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review.Semantic proximity
Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review.Semantic proximity
Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.Semantic proximity
Cost-effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR-mutated advanced non-small cell lung cancer.Semantic proximity
Camrelizumab In Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Cost-Effective Analysis In ChinaSemantic proximity
Cost-effectiveness of Osimertinib vs Docetaxel-bevacizumab in Third-line Treatment in EGFR T790M Resistance Mutation Advanced Non-Small Cell Lung Cancer in China.Semantic proximity
Cost-effectiveness analysis based on two models of sacituzumab tirumotecan versus platinum-based chemotherapy as second-line treatment in EGFR-mutant non-small-cell lung cancer.Semantic proximity
Cost-effectiveness analysis of first-line treatments for advanced epidermal growth factor receptor-mutant non-small cell lung cancer patients.Semantic proximity
Cost-effectiveness of sotorasib as a second-line treatment for non-small cell lung cancer with KRASG12C mutation in China and the United StatesSemantic proximity
Cost effectiveness of ceritinib in patients previously treated with crizotinib and chemotherapy with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) in the United StatesSemantic proximity
Cost-Effectiveness of First-Line Immunochemotherapy Versus BRAF Plus MEK Inhibitors in BRAFV600E-Mutated Metastatic Lung Cancer.Semantic proximity
Select a neighboring publication to make it the new centre.